novo nordisk hims - Search News

News

Novo Nordisk, Investor Attention

As Novo Nordisk ramps up lawsuits over Wegovy copies, investors ask where is Hims?

In Novo Nordisk’s legal fight against dozens of U.S. pharmacies and companies selling cheaper copies of its weight-loss drug Wegovy, one name remains conspicuously absent: Hims & Hers.

TipRanks on MSN · 3d

Novo Nordisk’s Promising Study on Heart Failure Treatment: What Investors Need to Know

Novo Nordisk (($DE:NOVA)) announced an update on their ongoing clinical study. Study Overview: Novo Nordisk is conducting an open-label extension

Zacks.com on MSN · 3d

Novo Nordisk A/S (NVO) is Attracting Investor Attention: Here is What You Should Know

Novo Nordisk (NVO) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the near future.

11h

Hims & Hers Stock Slips As FTC Probe Into Subscription Practices Resurfaces

Hims & Hers shares fall after a report says the FTC has investigated its cancellation policies and billing practices for over ...

TipRanks on MSN10h

Here’s Why Wall Street Is Cautious on Hims & Hers Health Stock (HIMS)

Telehealth and wellness platform Hims & Hers Health ($HIMS) recently disappointed investors with its mixed second-quarter ...

44m

Hims & Hers (HIMS) Drops Amid Reported Details Of FTC Investigation, Adding To Investor Scrutiny In Pending Securities Class Action - Hagens Berman

Investors with substantial losses have the opportunity (until August 25, 2025) to move the court for appointment as Lead Plaintiff. Shareholder rights firm Hagens Berman is investigating the legal ...

Hims & Hers: Still Growing After Breakup With Novo Nordisk

Hims & Hers is a top telehealth stock with strong revenue growth, innovative offerings, and long-term potential. Click here ...

23h

Hims & Hers stock drops after FTC probe report

Hims & Hers Health (NYSE:HIMS) stock fell 4.1% in after-hours trading on Thursday following a Bloomberg report that revealed ...

11d

Wegovy maker Novo hit with investor class action over revenue forecast cut

Novo Nordisk , maker of the weight-loss drug Wegovy, has been sued in U.S. court by investors claiming the Danish ...

Devdiscourse4d

Novo Nordisk's Legal Blitz: The Missing Piece in the Battle Against Compounded Weight-Loss Drugs

Novo Nordisk's legal actions against U.S. pharmacies over compounded copies of its drug Wegovy exclude Hims & Hers, a ...

10don MSN

Hims & Hers stock slides 5% after second quarter revenue misses forecasts

Hims & Hers Health stock fell as much as 5% early Tuesday after the company reported revenue late Monday that fell shy of ...

NJBIZ1mon

Novo Nordisk ends Hims & Hers deal over Wegovy knockoffs

Novo Nordisk is ending a partnership with Hims & Hers. The fallout comes over claims the telehealth platform sold copycat versions of the pharmaceutical giant’s weight-loss drug Wegovy.

15don MSN

Can Novo Nordisk’s New CEO Stop Rivals From Taking Over the Anti-Obesity Market?

Danish leader will face a challenging landscape among competitors ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results